Lepu Biopharma is a biopharmaceutical company focused on oncology, specifically targeting cancer treatment through antibody-drug conjugates (ADCs), oncolytic viruses, and immunotherapies. The company operates an integrated end-to-end platform covering drug discovery, clinical development, CMC, and GMP-compliant manufacturing, with production facilities in Beijing and Shanghai. Its core commercial product is MEIYOUHENG (Becotatug Vedotin Injection), while its pipeline includes candidates such as MRG001, MRG002, MRG003, and MRG007. Lepu Biopharma serves the Chinese market through its internal sales and marketing team and expands internationally via strategic partnerships, including a licensing agreement with ArriVent for MRG007. The company holds patents in China, the United States, Japan, the European Union, and other jurisdictions, and its products have been presented at major medical conferences such as ASH, ASCO, and ESMO.

Summarised from the company's own disclosures, fiscal year ended Apr 2026

Industry Biotechnology Homepage lepubiopharma.com
Sector Healthcare IR page lepubiopharma.com/investor
Tags
antibody-drug conjugates, oncology, oncolytic viruses, immunotherapy, drug discovery, clinical development, gmp manufacturing, cancer treatment, biopharmaceuticals, MEIYOUHENG, Becotatug Vedotin Injection, MRG001, MRG002, MRG003, MRG007, Taizhou Aoke, Lepu Beijing, CtM Bio, ArriVent
Press page lepubiopharma.com/news

Metrics

Valuation  
Market cap HK$ 4.55B
Market cap (USD) $ 579.859M
P/E 15.10
PEG —
P/BV 2.71
P/S 3.90
P/OCF -24.28
P/FCF —
Dividend yield —
Turnover / mcap 0.32%
Returns  
ROE 25.6%
ROI 10.9%
ROIC 11.9%
Profit margin 28.0%
Growth  
Revenue growing Yes
Profits growing Yes
Revenue up 3y Yes
Revenue up 5y —
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable Yes
Margin expanding Yes
Buying back stock No
Diluting (TTM) Yes
Debt/Equity 83.2%
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 13
Quality score 40.0%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
Revenue 934.869M 367.794M 225.352M 15.572M 0 757K
Net profit 261.364M -411.376M -22.096M -689.052M -1.011B -581.849M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
Share price 2.7 2.76 4.19 10.18 — —
Price performance 12m 0 -0.34 -0.61 — — —

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

自願性公告控股股東增持股份 Bull 1 Bear 0 Routine

本公告乃由樂普生物科技股份有限公司(「本公司」)董事(「董事」)會(「董事會」) 自願作出。 董事會接獲蒲忠傑博士(「蒲博士」,董事長兼執行董事,及本公司控股股東)通 知,彼已於2026年10月27日以其自有資金通過滬港通在公開市場按每股H股平均 價格約人民幣3.04元(約3.55港元)購買合共1,050,000股本公司H股(「H股」),相 當於於本公告日期本公司已發行股份(「股份」)總數約0.06%。 蒲博士告知董事會,增持本公司股份彰顯了其對本公司業務前景、增長潛力及長 期投資價值的堅定信心。特別是,蒲博士認為,本公司憑藉其創新驅動的研發及 商業化佈局,疊加積極的臨床數據及產品管線的巨大潛力,本公司將繼續穩佔優 勢。 緊隨增持股份後及於本公告日期,蒲博士(i)直接持有1,050,000 股H股;及(ii)通 過寧波厚德義民信息科技有限公司(一家由蒲博士間接全資擁有的公司)及樂普 (北京)醫療器械股份有限公司(一家蒲博士為實際控制人的公司)分別間接持有 433,239,436股H股及225,352,113股H股,相當於已發行股份總數約36.6%。據本 公司可獲公開查閱的資料及就董事所知,緊隨增持股份後及於本公告日期,本公 司繼續遵守上市規則項下的最低公眾持股量規定。

1

本公司股東及潛在投資者於買賣本公司股份時務請審慎行事。 承董事會命 樂普生物科技股份有限公司 董事長兼執行董事 蒲忠傑博士 中國,上海,2026年10月27日

於本公告日期,董事會包括執行董事蒲忠傑博士(董事長)及隋滋野博士(總經 理);非執行董事蒲珏女士及秦怡然女士;以及獨立非執行董事周德敏先生、楊海 峰先生及華風茂先生。

2

This announcement is made by the board (the “Board”) of directors (the “Directors”, each a “Director”) of Lepu Biopharma Co., Ltd. (the “Company”) on a voluntary basis. The Board has been informed by Dr. Pu Zhongjie (“Dr. Pu”), the chairman of the Board and executive Director, and a controlling shareholder of the Company, that he has purchased an aggregate of 1,050,000 H shares of the Company (the “ H Shares ” ) in the open market via Shanghai-Hong Kong Stock Connect on October 27, 2026 at an average price of approximately RMB3.04 (equivalent to HKD3.55) per H Share with his own funds, representing approximately 0.06% of the total number of issued shares of the Company (the “Shares”) as at the date of this announcement. Dr. Pu informed the Board that his increase in shareholding in the Company demonstrates his sustained confidence in the business prospects, growth potential and long-term investment value of the Company. In particular, Dr. Pu believes that the Company continues to be well-positioned to benefit from its innovation-driven approach in its R&D and commercialization efforts, supported by promising clinical data and the vast potential of its products pipeline. Immediately following the increase in shareholding and as at the date of this announcement, Dr. Pu holds (i) directly 1,050,000 H Shares and (ii) indirectly holds 433,239,436 H Shares and 225,352,113 H Shares through Ningbo Houde Yimin Information Technology Co., Ltd. (寧波厚 德義民信息科技有限公司, a company indirectly wholly-owned by Dr. Pu) and Lepu Medical Technology (Beijing) Co., Ltd. (樂普(北京)醫療器械股份有限公司, a company of whom Dr. Pu is the actual controller), respectively, representing approximately 36.6% of the total number of issued Shares. Based on the information that is publicly available to the Company and to the knowledge of the Directors, immediately following the increase in shareholding and as at the date of this announcement, the Company continues to comply with the minimum public float requirement under the Listing Rules.

1

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company. By order of the Board Lepu Biopharma Co., Ltd. Dr. Pu Zhongjie Chairman of the Board and Executive Director Shanghai, the PRC, October 27, 2026

As at the date of this announcement, the Board comprises Dr. Pu Zhongjie (chairman) and Dr. Sui Ziye (chief executive officer) as executive Directors; Ms. Pu Jue and Ms. Qin Yiran as non-executive Directors; and Mr. Zhou Demin, Mr. Yang Haifeng and Mr. Fengmao Hua as independent non-executive Directors.

2

1

LEPU BIOPHARMA CO., LTD.

2157

2026ESMO CMG901 (AZD0901)LBA MRG007LBA MRG003

i CMG901 (AZD0901)2L+CLDN18.2 GECIIIiiMRG007 (ARR-217) CRCCDH17ADC iiiPD-1(HX008)MRG003 LA-HNSCCII CMG901 (AZD0901) LBA CLARITY-Gastric01CG-01III INVsonesitatug vedotinSone-Ve 3L+ITT OSSone-Ve CLDN18.2GEC

2 CG-01IIISone-Ve GECCLDN18.2≥25% (2L+) CLDN18.2ITT1:1:1 Sone-Ve 1.8 mg/kgSone-Ve 2.2 mg/kg 1:1Sone-Ve 2.2 mg/kg2L 3L

OSITT BICRPFSITTOS 2026531594532 Sone-Ve 2.2 mg/kgn=267INVn=265 8.6Sone-Ve 2.2 mg/kg OS10VS5HR 0.47 95% CI 0.36-0.62p 0.001(ITT)OS 10.6VS6.4HR 0.58 95% CI 0.47-0.73p0.001BICR (PFS) CLDN18.2≥75%HR 0.5995% CI 0.45-0.78 ≥25%75%HR 0.6395% CI 0.42-0.94

Sone-VeINV 3L+ (n)178177 OS(95% CI)10.0 (7.2-11.4)5.0 (4.2-6.4) HR(95% CI)0.47 (0.36-0.62)– p<0.001– ITT (2L+)(n)267265 OS(95% CI)10.6 (9.1-12.0)6.4 (5.8-7.6) HR(95% CI)0.58 (0.47-0.73)– p<0.001– BICRPFS(95% CI)4.2 (3.5-5.3)3.8 (3.0-4.2) HR(95% CI)0.77 (0.62-0.96)– p0.05–

3 Sone-VeINV *(SAS)TRAE(n)261252 224 (85.8)205 (81.3) ≥395 (36.4)113 (44.8) 29 (11.1)16 (6.3) 20 (7.7)40 (15.9) 3 (1.1)2 (0.8) 8 (3.1)11 (4.4)

  •   SASTRAE
    

MRG007 (ARR-217) LBA MRG007 (ARR-217)I CRC

IbCRCGI

I202685 123113CRC2 mg/kg4 mg/ kg6 mg/kg8 mg/kg4-8 mg/kg CRCCRC 31-9 ORRCRC6 mg/kgORR 44.8%13/2995% CI26.4%-64.3%93.1% (27/29)RAS RASORR50.0% (4/8) 42.1% (8/19)4 mg/kgCRCORR34.2% 25/7395% CI23.5%-46.3% MRG007 (ARR-217) TEAE12 1231(0.8%)TEAE ADCADC

4 MRG003 MRG003GORTEC 2024-03 IDEAL

(a) PD-1(HX008)MRG003A(b) MRG003 BCRTII LA-HNSCCCRT LA-HNSCC p16p161:1 CRT12CR FlemingCR30%106 201 20251023202642149 3119p162010 4TEAE8A 6B2113TEAEA3TEAE1 ALT11 111 B3TEAE1ALT1 ORRRECIST 1.1 ORR71% CMG901 (AZD0901) CMG901sonesitatug vedotinAZD0901CLDN18.2ADC CLDN18.2E MMAECLDN18.2 ADCCLDN18.2GC 20267CLARITY-Gastric01 III sonesitatug vedotin2L+ Claudin 18.2GC OS CMG901 (AZD0901) CLDN18.2ADC20232CMG901 CLARITY-Gastric01 CMG901 (AZD0901)IIIAZD0901

5 MRG007 (ARR-217) CRC190CRC 51

MRG007CRCCDH17 ADCCDH17 CRC CDH17 ADC20251ArriVent BioPharma, Inc. ArriVentMRG007 ArriVentCRCIb MRG003 MRG003EGFRMMAE ADC EGFR 202510MRG003 EGFR ADCMRG003

CMG901 (AZD0901)MRG007 (ARR-217) MRG003

6

20261026

Prompts

Lepu Biopharma Co., Ltd. (ticker 2157), listed in Hong Kong.

ETFs Holding Lepu Biopharma Co., Ltd.

ETF Weight in ETF Shares Market value As of
AVEE 0.04% 145,000 $ 49.141K Nov 16, 2026
DFEM 0.00% 166,000 $ 59.251K Nov 12, 2026
AVEM 0.00% 557,000 $ 188.77K Nov 16, 2026